If this hypothesis is true, it would form a basis for investigating the effectiveness of combined anticoagulant/antiplatelet regimens and anti-TGF-β therapy to make anticoagulant/antiplatelet therapy of cancer patients experiencing CAT more effective and safe. This evidence concerns the gene TGFB1 and cancer.